Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Cohen, Jeffrey A; Bermel, Robert; Grossman, Cynthia; Hersh, Carrie; Hyland, Megan; Mowry, Ellen; Tintore Subirana, Mar; Zabalza de Torres, Ana; Montalban Gairín, Xavier

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Cohen, Jeffrey A
dc.contributor.author	Bermel, Robert
dc.contributor.author	Grossman, Cynthia
dc.contributor.author	Hersh, Carrie
dc.contributor.author	Hyland, Megan
dc.contributor.author	Mowry, Ellen
dc.contributor.author	Tintore Subirana, Mar
dc.contributor.author	Zabalza de Torres, Ana
dc.contributor.author	Montalban Gairín, Xavier
dc.date.accessioned	2022-09-07T12:14:43Z
dc.date.available	2022-09-07T12:14:43Z
dc.date.issued	2022-06
dc.identifier.citation	Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, et al. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Mult Scler J. 2022 Jun;28(7):1131–7.
dc.identifier.issn	1477-0970
dc.identifier.uri	https://hdl.handle.net/11351/8057
dc.description	Esclerosi múltiple; Vacunació SARS-COV-2; Resposta immune humoral
dc.description.sponsorship	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Biogen (Cambridge, MA, USA). Funding for writing and editorial support was provided by Biogen.
dc.language.iso	eng
dc.publisher	SAGE Publications
dc.relation.ispartofseries	Multiple sclerosis Journal;28(7)
dc.rights	Attribution-NonCommercial 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/
dc.source	Scientia
dc.subject	Esclerosi múltiple - Tractament
dc.subject	Immunoglobulina G
dc.subject	COVID-19 (Malaltia) - Vacunació
dc.subject.mesh	Immunoglobulin G
dc.subject.mesh	Multiple Sclerosis
dc.subject.mesh	Viral Vaccines
dc.title	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1177/13524585211061343
dc.subject.decs	inmunoglobulina G
dc.subject.decs	esclerosis múltiple
dc.subject.decs	vacunas víricas
dc.relation.publishversion	https://doi.org/10.1177/13524585211061343
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Cohen JA, Bermel RA] Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. [Grossman CI] Biogen, Cambridge, MA, USA. [Hersh CM] Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA. [Hyland M] Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. [Mowry EM] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [Tintorè M, Zabalza A, Montalban X] Servei de Neurologia i Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid	34994577
dc.identifier.wos	000740936300001
dc.rights.accessrights	info:eu-repo/semantics/openAccess